The trial was registered with the Australian New Zealand Clinical Trials Registry (registration # ACTRN12605000362695).
Effects of N-acetyl cysteine on cognitive function in bipolar disorder
Article first published online: 16 OCT 2012
© 2012 The Authors. Psychiatry and Clinical Neurosciences © 2012 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 66, Issue 6, pages 514–517, October 2012
How to Cite
Dean, O. M., Bush, A. I., Copolov, D. L., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M. and Berk, M. (2012), Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry and Clinical Neurosciences, 66: 514–517. doi: 10.1111/j.1440-1819.2012.02392.x
- Issue published online: 16 OCT 2012
- Article first published online: 16 OCT 2012
- Manuscript Accepted: 8 AUG 2012
- Manuscript Revised: 6 AUG 2012
- Manuscript Received: 21 MAR 2012
- Australian New Zealand Clinical Trials Registry. Grant Number: ACTRN12605000362695
- Simons Autism Foundation
- Cancer Council of Victoria
- Stanley Medical Research Foundation
- Beyond Blue
- Geelong Medical Research Foundation
- Bristol Myers Squibb
- Eli Lilly
- Mayne Pharma and Servier
- 2Cognitive impairment in bipolar disorder. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2011;155: 19–26., , , .
- 6N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 2011; 36: 78–86., , .